Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

  • Amrita Goyal
  • Joi B. Carter
  • Jeffrey A. Barnes
  • Lyn McDivitt DuncanEmail author


Primary cutaneous diffuse large B-cell lymphoma (pcDLBCL), leg type, is a rare B-cell lymphoma of post-germinal B cells. Although this lymphoma classically presents on the leg with erythematous or violaceous tumors or nodules, it can also present elsewhere on the body. Patients with pcDLBCL have a moderately poor prognosis and experience frequent systemic dissemination. Though small case series have reported dramatic improvements in survival with combination chemotherapy and rituximab, treatment is largely limited by patient age and functional status. This chapter discusses the clinical presentation, prognosis, treatment, histopathology, immunohistochemistry, molecular characteristics, and differential diagnosis of pcDLBCL. The chapter closes with two clinical cases: one case of pcDLBCL occurring on the leg and one occurring on the scalp.


Primary cutaneous diffuse large B-cell lymphoma, leg type pcDLBCL CD20 Bcl2 Bcl6 FoxP1 Centroblast Immunoblast MALT lymphoma Pseudolymphoma 


  1. 1.
    Meijer CJLM, Vergier B, Duncan LM, Willemze R. Primary cutaneous DLBCL, leg type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 242.Google Scholar
  2. 2.
    Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064–73.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Paulli M, Viglio A, Vivenza D, Capello D, Rossi D, Riboni R, et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol. 2002;33:937–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Bessell EM, Humber CE, O’Connor S, English JSE, Perkins W, Dickinson PD, et al. Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification. Br J Dermatol. 2012;167:1118–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106:2491–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25:1581–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Vermeer MH, Geelen F, van Haselen CW, van Voorst Vader PC, Geerts M-L, van Vloten WA, et al. Primary cutaneous large B-cell lymphoma of the leg. Arch Dermatol. 1996;132:1304–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys. 2013;87:719–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Bergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type. Arch Dermatol. 2007;143:1144–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152–62.PubMedGoogle Scholar
  11. 11.
    Brogan BL, Zic JA, Kinney MC, Hu JY, Hamilton KS, Greer JP. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol. 2003;49:223–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol. 2009;145:329–30.PubMedGoogle Scholar
  13. 13.
    Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Posada-Garcia C, Florez A, Pardavila R, Garcia-Cruz A, Amador L, Alvarez M, et al. Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy. Eur J Dermatol. 2009;19:393–4.Google Scholar
  17. 17.
    Hallermann C, Niermann C, Fischer R-J, Schulze H-J. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol. 2007;56:588–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139:515–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Desouki MM, Post GR, Cherry D, Lazarchick J. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res. 2010;8:84–8.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hallermann C, Kaune KM, Gesk S, Martin-Subero JI, Gunawan B, Griesinger F, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol. 2004;123:213–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24:296–305.PubMedCrossRefGoogle Scholar
  22. 22.
    Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129:1149–55.PubMedCrossRefGoogle Scholar
  23. 23.
    Espinet B, García-Herrera A, Gallardo F, Baró C, Salgado R, Servitje O, et al. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. Histol Histopathol. 2011;26:213–21.PubMedGoogle Scholar
  24. 24.
    Grange F, Petrella T, Beylot-Barry M, Joly P, D’Incan M, Delaunay M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103:3662–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Felcht M, Heck M, Weiss C, Becker JC, Dippel E, Müller CSL, et al. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol. 2012;167:348–58.PubMedCrossRefGoogle Scholar
  26. 26.
    Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Sterry W, Kruger GR, Steigelder G-K. Skin involvement in malignant B-cell lymphomas. J Dermatol Surg Oncol. 1984;10:276–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Muniesa C, Pujol RM, Estrach MT, Gallardo F, García-Muret MP, Climent J, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features. J Am Acad Dermatol. 2012;66:650–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Demirkesen C, Tüzüner N, Esen T, Lebe B, Ozkal S. The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma. Leuk Res. 2011;35:1269–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol. 2010;34:1043–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009;10:895–902.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferreri AJM, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. Br J Haematol. 2004;127:173–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Orwat DE, Batalis NI. Intravascular large B-cell lymphoma. Arch Pathol Lab Med. 2012;136:333–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 158–66.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Amrita Goyal
    • 1
  • Joi B. Carter
    • 2
  • Jeffrey A. Barnes
    • 3
  • Lyn McDivitt Duncan
    • 4
    Email author
  1. 1.Harvard-MIT Division of Health Sciences and TechnologyHarvard Medical SchoolBostonUSA
  2. 2.Department of DermatologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  3. 3.Comprehensive Cutaneous Lymphoma Program, Department of MedicineMassachusetts General Hospital Cancer CenterBostonUSA
  4. 4.Dermatopathology Service, Department of PathologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations